Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine
Public ClinicalTrials.gov record NCT03854110. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GP-2250 With Gemcitabine in Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma Following Progression on 5-FU-based Chemotherapy
Study identification
- NCT ID
- NCT03854110
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Geistlich Pharma AG
- Industry
- Enrollment
- 64 participants
Conditions and interventions
Conditions
Interventions
- GP-2250 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 13, 2019
- Primary completion
- Jun 29, 2026
- Completion
- Jun 29, 2026
- Last update posted
- Sep 10, 2025
2019 – 2026
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Hoag Family Cancer Institute | Newport Beach | California | 92663 | — |
| University of Kansas Cancer Center | Fairway | Kansas | 66205 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Wake Forest Baptist Health | Winston-Salem | North Carolina | 27292 | — |
| Abramson Cancer Center at the University of Pennsylvania | Phildelphia | Pennsylvania | 19104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03854110, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 10, 2025 · Synced Apr 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03854110 live on ClinicalTrials.gov.